China Pharma Holdings (CPHI) Long-Term Deferred Tax (2011 - 2026)

China Pharma Holdings has reported Long-Term Deferred Tax for 11 years, with the latest figure at $21.8 million in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 0.54% year-over-year to $21.8 million; the trailing twelve-month figure through Mar 2026 stood at $21.8 million (down 0.54% YoY), and the FY2025 full-year result was $21.2 million, down 2.3% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $21.8 million, up from $21.2 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $22.7 million in Q3 2025, with the low at $21.2 million in Q4 2025.
• Historically, Long-Term Deferred Tax has averaged $21.9 million across 5 years, with a median of $21.9 million in 2025.
• Annual changes were most pronounced in 2022 — Long-Term Deferred Tax retreated 8.33% — and 2024, when it rose 0.78%.
• China Pharma Holdings' Long-Term Deferred Tax stood at $22.0 million in 2022, then declined by 2.07% to $21.5 million in 2023, then grew by 0.78% to $21.7 million in 2024, then slipped by 2.3% to $21.2 million in 2025, then grew by 2.83% to $21.8 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $21.8 million (Q1 2026), $21.2 million (Q4 2025), and $22.7 million (Q3 2025), per Business Quant data.